BR112023025318A2 - Derivados de triazina e seu uso no tratamento do câncer - Google Patents

Derivados de triazina e seu uso no tratamento do câncer

Info

Publication number
BR112023025318A2
BR112023025318A2 BR112023025318A BR112023025318A BR112023025318A2 BR 112023025318 A2 BR112023025318 A2 BR 112023025318A2 BR 112023025318 A BR112023025318 A BR 112023025318A BR 112023025318 A BR112023025318 A BR 112023025318A BR 112023025318 A2 BR112023025318 A2 BR 112023025318A2
Authority
BR
Brazil
Prior art keywords
triazine derivatives
cancer treatment
compounds
cancer
treatment
Prior art date
Application number
BR112023025318A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Tosstorff Andreas
Angélique Patiny-Adam
Christian Schnider
Georg Jaeschke
Aurelie Bouche Lea
Sandra Steiner
Katharina Mesch Stefanie
Wolfgang Guba
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112023025318A2 publication Critical patent/BR112023025318A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112023025318A 2021-06-04 2022-06-02 Derivados de triazina e seu uso no tratamento do câncer BR112023025318A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21177660 2021-06-04
EP21188639 2021-07-30
EP21215875 2021-12-20
PCT/EP2022/064995 WO2022253936A1 (en) 2021-06-04 2022-06-02 Triazine derivatives and their use in the treatment of cancer.

Publications (1)

Publication Number Publication Date
BR112023025318A2 true BR112023025318A2 (pt) 2024-02-27

Family

ID=82115763

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025318A BR112023025318A2 (pt) 2021-06-04 2022-06-02 Derivados de triazina e seu uso no tratamento do câncer

Country Status (16)

Country Link
US (3) US20240132471A1 (https=)
EP (1) EP4347571B1 (https=)
JP (2) JP7705963B2 (https=)
KR (1) KR20240019083A (https=)
AR (1) AR126053A1 (https=)
AU (1) AU2022287224A1 (https=)
BR (1) BR112023025318A2 (https=)
CA (1) CA3216026A1 (https=)
CL (1) CL2023003491A1 (https=)
CO (1) CO2023016212A2 (https=)
CR (1) CR20230566A (https=)
IL (1) IL307201A (https=)
MX (1) MX2023013998A (https=)
PE (1) PE20240928A1 (https=)
TW (1) TW202313577A (https=)
WO (1) WO2022253936A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CA3218212A1 (en) * 2021-04-28 2022-11-03 Astellas Pharma Inc. Substituted triazine compound
TW202313577A (zh) * 2021-06-04 2023-04-01 瑞士商赫孚孟拉羅股份公司 新穎化合物
IL314025A (en) * 2022-01-07 2024-08-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and uses thereof
EP4558499A1 (en) * 2022-07-21 2025-05-28 F. Hoffmann-La Roche AG Nlrp3 inhibitors
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2023371859A1 (en) * 2022-11-04 2025-06-12 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and use thereof
PE20251845A1 (es) * 2022-12-07 2025-07-17 Hoffmann La Roche Compuestos novedosos como moduladores de la inhibicion de nlrp3
JP2026511027A (ja) * 2023-03-20 2026-04-10 インシリコ メディスン アイピー リミティド Nlrp3インフラマソーム阻害剤及びその使用
WO2024193699A1 (zh) * 2023-03-23 2024-09-26 成都赜灵生物医药科技有限公司 三嗪类化合物及其用途
TW202448448A (zh) * 2023-04-19 2024-12-16 瑞士商赫孚孟拉羅股份公司 新穎化合物
AU2024258000A1 (en) * 2023-04-19 2025-08-14 F. Hoffmann-La Roche Ag Oxazolo[4,5-b]pyrazine and oxazolo[4,5-b]pyridine derivatives as nlrp3 inhibitors for the treatment of e.g. inflammatory diseases
KR20260027946A (ko) 2023-06-02 2026-03-03 머크 샤프 앤드 돔 엘엘씨 Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
CN121586712A (zh) * 2023-07-28 2026-02-27 豪夫迈·罗氏有限公司 新颖化合物
WO2025046419A1 (ko) * 2023-08-25 2025-03-06 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025252772A1 (en) * 2024-06-06 2025-12-11 F. Hoffmann-La Roche Ag Triazine derivatives
WO2026046981A1 (en) 2024-08-28 2026-03-05 F. Hoffmann-La Roche Ag Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028440A1 (en) * 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
KR20200087759A (ko) 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
MX2020009957A (es) * 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
EP4093509A1 (en) 2020-01-22 2022-11-30 F. Hoffmann-La Roche AG Sulfonimidamide compounds as nlrp3 modulators
CN115279739B (zh) 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
WO2022135567A1 (zh) 2020-12-25 2022-06-30 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
EP4289823A4 (en) 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CA3218212A1 (en) 2021-04-28 2022-11-03 Astellas Pharma Inc. Substituted triazine compound
TW202313577A (zh) * 2021-06-04 2023-04-01 瑞士商赫孚孟拉羅股份公司 新穎化合物
CN115433163A (zh) 2021-06-05 2022-12-06 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
LT4363406T (lt) 2021-07-02 2025-12-29 Astrazeneca Ab Nlrp3 inflamasomų inhibitoriai
WO2023028536A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技(浙江)有限公司 一种含氮化合物、其制备方法及应用
IL314025A (en) 2022-01-07 2024-08-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and uses thereof
CA3246681A1 (en) 2022-03-25 2023-09-28 Ventus Therapeutics U.S., Inc. PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES
JPWO2024090469A1 (https=) 2022-10-26 2024-05-02
CN115621720A (zh) * 2022-10-27 2023-01-17 永道射频技术股份有限公司 一种应用于rfid读写器的全息超材料阵列天线
AU2023371859A1 (en) 2022-11-04 2025-06-12 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and use thereof
TW202440107A (zh) 2022-12-28 2024-10-16 瑞典商阿斯特捷利康公司 Nlrp3炎症小體抑制劑
WO2024169858A1 (zh) 2023-02-17 2024-08-22 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途

Also Published As

Publication number Publication date
JP2025098157A (ja) 2025-07-01
US12421209B2 (en) 2025-09-23
US20240132471A1 (en) 2024-04-25
CO2023016212A2 (es) 2023-12-11
US20250276958A1 (en) 2025-09-04
TW202313577A (zh) 2023-04-01
JP2024522494A (ja) 2024-06-21
CL2023003491A1 (es) 2024-05-24
AR126053A1 (es) 2023-09-06
KR20240019083A (ko) 2024-02-14
US20250197370A1 (en) 2025-06-19
CA3216026A1 (en) 2022-12-08
MX2023013998A (es) 2023-12-11
EP4347571A1 (en) 2024-04-10
IL307201A (en) 2023-11-01
JP7705963B2 (ja) 2025-07-10
PE20240928A1 (es) 2024-04-30
EP4347571B1 (en) 2026-04-22
CR20230566A (es) 2024-01-22
WO2022253936A1 (en) 2022-12-08
AU2022287224A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
BR112023025318A2 (pt) Derivados de triazina e seu uso no tratamento do câncer
BR112023023527A2 (pt) Inibidores de nlrp3
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
BR112023003580A2 (pt) Compostos heterocíclicos
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
MX2026001061A (es) Inhibidores de la fosfatidilinositol 3-cinasa (pi3k)
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
BR112015018751A2 (pt) derivados de piridazinona macrocíclicos
BR112022018828A2 (pt) Derivados de benzodiazepina como gaba a gamma1 pams
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
BR112022003982A2 (pt) Compostos heterocíclicos
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
JOP20190130A1 (ar) مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112022016432A2 (pt) Compostos heterocíclicos de heteroarila e usos dos mesmos
BR112020016929A8 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
BR112022001390A2 (pt) Inibidores de enzima
BR112022026397A2 (pt) Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila
BR112022000936A2 (pt) Inibidores de enzimas
BR112021026899A2 (pt) Compostos heterocíclicos